Skip to main content
. Author manuscript; available in PMC: 2019 Apr 15.
Published in final edited form as: Clin Cancer Res. 2018 Feb 6;24(8):1795–1804. doi: 10.1158/1078-0432.CCR-17-3351

Figure 2. HER2-positive BCBM (DFBM-355) has differential drug sensitivity when implanted in the brain compared to mammary gland of SCID mouse.

Figure 2

A) Kaplain-Meier survival curves of DF-BM355/-bearing mice show improved survival by treatment with dual PI3K + mTOR inhibition [BKM120 (30 mg/kg, PO) + RAD001 (7.5 mg/kg, QD)] but not with single agent PI3K, HER2 (lapatinib, 100 mg/kg PO) or mTOR drug inhibition (n=5–18). Adapted from Ni et al, Nat Med 2016. B) When implanted in the mammary gland (MG), DFBM-355 tumor growth inhibition by PI3K+mTOR (BKM+RAD) is equivalent to PI3K+HER2 (BKM+LAP) or HER2+mTOR (LAP+RAD) inhibition. Data shown as mean ± SEM, (n=6–8). Difference tested by two-way ANOVA, followed by Dunnett’s multiple comparison test ** P < 0.01. C) AKT/mTOR gene signature expression is reduced in DFBM-355 implanted in mammary gland compared to the brain. Data are represented as mean ± SD (n = 3–5 per group; difference tested by t-test. P = 0.0004).